Quick Facts

• Primary Use: Management of specific forms of erectile dysfunction.
• Key Action: May support enhanced physical capacity.
• Availability: Use is contingent on advice and supervision from a healthcare professional.

---

What Yi Li Treats: Main Uses and Benefits

Yi Li (also referred to as Yi Li Xiao Capsule in some contexts) is an agent that has been investigated for use in specific therapeutic areas. It is an available option intended for the management of certain symptoms associated with erectile dysfunction. The proper use of this product is contingent upon the advice and supervision of a healthcare professional. Due to the potential presence of an undeclared prescription drug substance (tadalafil), it may pose serious health risks if taken without medical oversight, especially when used in combination with other medications.

Patients considering this agent should review detailed safety alerts for necessary safety and usage information. This medication may support certain bodily functions. All prescription drugs should be utilized exclusively under the guidance of a healthcare provider because they are used to address specific conditions and may be associated with serious effects. It is vital to consult with a doctor to ascertain if this product is an appropriate element of a treatment plan.

Who Can and Cannot Use Yi Li?

Yi Li (Nisoldipine) eligibility is strictly determined by official regulatory labeling, defining populations for whom use is permitted, restricted, or absolutely contraindicated.

Contraindications and Non-Eligibility

Category	Non-Eligibility Rule
Absolute Contraindication	Patients with known hypersensitivity to Nisoldipine or other dihydropyridine calcium channel blockers must not use this medicine.
Concomitant Use	Co-administration with strong CYP3A4 enzyme inhibitors or consumption of grapefruit products is prohibited.
Pediatric Use	Safety and efficacy have not been established in children and adolescents.

---

Restricted and Conditional Use

Eligibility is limited or conditional for certain groups, requiring special consideration as stated in the official prescribing information:

• Geriatric Patients: Use requires initiation with a lower starting dose due to higher drug concentrations observed in older adults.
• Hepatic Impairment: Patients with liver impairment, such as cirrhosis, require a lower starting and maintenance dose.
• Pregnancy and Lactation: Use is not recommended or avoided due to a lack of adequate, controlled clinical data in these physiological states.

Standard use is established only for the general adult population.

The interaction profile for Yi Li is primarily determined by its active substance, Nisoldipine, which is extensively metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. This major pharmacokinetic relationship forms the basis for several official restrictions.

Co-administration with strong CYP3A4 inhibitors, such as the antifungal agents Itraconazole and Ketoconazole, is formally classified as contraindicated in regulatory documents. This prohibition exists because these medicines substantially reduce the metabolic clearance of Nisoldipine, increasing systemic exposure and the resulting risk of adverse effects. Conversely, the use of strong CYP3A4 inducers, including Phenytoin or Rifamycins, is officially documented to decrease Nisoldipine plasma concentrations, which may compromise its intended therapeutic action over time.

A significant drug-food restriction applies to all grapefruit products (juice and food), which are also contraindicated due to their inhibitory effect on intestinal CYP3A4 activity. The regulatory label specifically requires that consumption of these products must be avoided for at least one hour before and after taking the medication to mitigate the risk of interaction.

A pharmacodynamic interaction exists with other medicines that lower blood pressure, such as beta-adrenergic blocking agents. This combination carries a documented risk of additive effects, particularly severe hypotension. Additionally, high-fat meals are documented to alter the absorption kinetics, increasing the peak concentration ( Cmax) while reducing overall exposure. Clearance is also compromised in patients with hepatic impairment, a population consideration that elevates the potential severity of all drug-drug interactions.

Targeted Inhibition of L-type Calcium Channels

The core mechanism of Yi Li involves the active ingredient, Nisoldipine, acting as an inhibitor with specific selectivity for the L-type Voltage-Dependent Calcium Channel ( CaV1.2). These channels, predominantly found on the surface of peripheral arterial smooth muscle cells, are the molecular targets where the drug binds to block the influx of extracellular calcium ions ( Ca^2+). This action initiates the mechanistic cascade that influences signaling within the vascular system.

---

Cascade Leading to Vascular Smooth Muscle Relaxation

By preventing the increase in intracellular Ca^2+ concentration, Nisoldipine interrupts the biochemical sequence known as the excitation-contraction coupling pathway. This disruption prevents the activation of MLCK, which normally initiates muscle contraction. The resulting physiological effect is the relaxation and widening of the systemic resistance arteries, a process known as vasodilation.

---

Selective Modulation of Peripheral Resistance

Nisoldipine’s mechanism exhibits vascular selectivity, focusing its action on the peripheral blood vessels with minimal direct effect on the heart rate or cardiac contractility. The resulting widespread arterial widening decreases the load on the heart by reducing the Peripheral Vascular Resistance (PVR), which results in an alteration of the systemic blood pressure.

How to Use Yi Li

Yi Li, which contains the active ingredient Nisoldipine, is administered as an oral extended-release tablet and is intended for long-term, chronic administration. The extended-release formulation dictates a once-daily (Q.D.) dosing frequency to maintain consistent systemic concentrations of the medication throughout a 24-hour period.

Official Administration Guidelines

Administration Constraint	Procedural Requirement
Route of Administration	Oral administration only.
Physical Handling	The tablet must be swallowed whole and must not be chewed, divided, or crushed to preserve the controlled-release mechanism.
Timing with Food	Administration is required on an empty stomach, specifically 1 hour before or 2 hours after a meal.

The standard initial dose is typically 17 mg once daily. Dosing may be adjusted (titrated) upward based on the prescribed regimen, usually at intervals of 7 to 14 days, up to a maximum recommended dose of 34 mg once daily.

Population-Specific Dosing

The usage protocol specifies modifications for certain patient populations. For individuals with impaired liver function (hepatic impairment), treatment should be initiated at a reduced dose of 8.5 mg once daily. In contrast, no initial dose adjustment is typically required for patients with renal impairment. These guidelines are foundational to the official administration protocol and are designed to ensure consistent delivery of the medicine.

Research evidence / Overview of studies for Yi Li (Nisoldipine)

---

Evidence for Use in Managing High Blood Pressure

Yi Li's active ingredient, Nisoldipine, was evaluated primarily through Randomized Controlled Trials (RCTs). These studies were used in research exploring how blood pressure levels change over time. In these trials, researchers evaluated the medication against an inactive substance (placebo) and against active comparator treatments. Primary outcomes related to systemic or functional imbalance that were monitored included sustained changes in the upper and lower blood pressure readings. Longer-term studies also tracked outcomes such as major cardiovascular events, including stroke and myocardial infarction, in the studied populations.

Findings describe patterns observed in the studies related to measured outcomes in the observed populations, which primarily included adults with essential hypertension. Research highlights changes measured during the study period, showing patterns related to sustained blood pressure measurements over the course of a day. However, long-term effects are not fully established, particularly regarding the incidence of these major events in certain patient cohorts. Also, some of the initial evidence was derived from studies using older, short-acting formulations of the drug, and results apply only to the populations studied.

---

Evidence for Use in Chronic Stable Angina

The use of Yi Li was also evaluated in research for conditions involving periods of episodic symptoms, specifically chronic stable angina pectoris (chest pain). Studies explored this condition using Randomized Controlled Trials. These trials monitored physiological strain by measuring a patient’s ability to exercise and the time it took before chest pain occurred. Patient-reported outcomes describing perceived discomfort were also collected, such as the reported frequency of angina episodes.

Findings describe patterns observed in the studies related to these outcomes. Researchers measured changes in reported exercise capacity and monitored the frequency of chest pain episodes. What remains uncertain is the long-term outcomes regarding the progression of the underlying disease. Studies monitored the progression of vessel narrowing (atherosclerosis) in the heart arteries over several years, and research describes that these findings were mixed regarding whether the medication was associated with the anatomical changes of the condition itself.

---

What Remains Uncertain About the Research

Research highlights what is known and what is still uncertain about the medication. One key limitation is that evidence quality varies across studies, and some older reported patterns may not be directly relevant to the current extended-release formulation. Comparative evidence is lacking regarding the long-term measurements of major event reduction against all available drug classes in every possible patient subgroup. Research provides context on group patterns, but findings were mixed in certain areas, meaning certainty remains low in predicting long-term outcomes for every individual with varied health profiles.

Key Studies & References

1. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study

The storage and disposal of Yi Li (Nisoldipine extended-release tablets) must strictly adhere to the conditions mandated in official regulatory labeling.

Official Storage Conditions

Requirement	Specifics Mandated by Regulatory Labeling
Temperature	Store at Controlled Room Temperature (20 mathrmC to 25 mathrmC).
Protection	Must be protected from moisture and protected from light.
Packaging	Store in the original container and keep the container tightly closed.
Child-Safety	Must be kept out of the sight and reach of children.

These constraints are essential for maintaining the stability and potency of the extended-release formulation over its shelf-life. Unused or expired Yi Li must be disposed of according to local regulations for pharmaceutical waste, such as utilizing a drug take-back program or following official guidelines for secure household disposal.